



## Re: Effect of Individual Omega-3 Fatty Acids on the Risk of Prostate Cancer: A Systematic Review and Dose-Response Meta-Analysis of Prospective Cohort Studies

Shinkan Tokudome

Department of Nutritional Epidemiology, National Institute of Health and Nutrition, Tokyo, Japan

Received May 11, 2015; accepted June 10, 2015; released online August 5, 2015

Copyright © 2015 Shinkan Tokudome. This is an open access article distributed under the terms of Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Dear Editor-in-Chief,

Recently, Fu et al (*JE*, 2015;25:261–74)<sup>1</sup> conducted a meta-analysis based on prospective cohort studies and clarified the association of prostate cancer (PCa) onset with dietary intake and blood concentrations of individual omega-3 fatty acids (or n-3 polyunsaturated fatty acids [PUFAs]). However, they could not find consistent dose-response relationships between PUFA intake/blood levels and PCa risk. Although the authors mentioned possible reasons for this lack of an observed relationship, I would like to add several more.

Their review was based on literature reported from Western countries, largely from the United States, where n-6 PUFA intake is much higher, n-3 PUFA intake much lower, and the ratio of n-6 PUFAs:n-3 PUFAs (or arachidonic acid [AA]:long-chain [LC] n-3 PUFAs) is much higher than in Asian countries/areas (including Japan), as discussed by the researchers.<sup>2,3</sup> The results appear to be most generalizable to the people of Western countries where the population shares a common genetic background and lifestyle factors with Western populations.

Furthermore, the authors' observations may not be biologically plausible. As is well-known, n-6 PUFAs (mainly linoleic acid) are upstream chemicals of the cyclooxygenase pathway, including AA and prostaglandin E2.<sup>4,5</sup> On the other hand, n-3 PUFAs (including  $\alpha$ -linolenic acid) are precursor substances of LC n-3 PUFAs, such as eicosapentaenoic acid, docosapentaenoic acid, and docosahexaenoic acid. n-6 PUFAs act as inflammatory and carcinogenic chemicals, while n-3 PUFAs are anti-inflammatory and anti-carcinogenic. In addition, not only absolute consumption and blood concentrations of fatty acids but also ratios of n-6 PUFAs:n-3 PUFAs and AA:LC n-3 PUFAs seem crucial for the onset of cancers,<sup>6–8</sup> including PCa.<sup>9</sup>

Several epidemiologic aspects of primary prevention should be taken into account. We need to clearly hypothesize etiologic factors in terms of cancer initiators or promoters. Because PCa has a long natural history, it is very difficult to

obtain information on etiologic factors from the distant past; this information bias may therefore unduly influence epidemiologic research (case-control studies in particular). Subjects with latent cancer could be misclassified into a control group due to the fact that it is prevalent not only in industrialized countries but also worldwide.

Age and family history are clear risk factors for PCa, but no definite modifiable preventive or risk factors are available to date.<sup>10</sup> Probable/limited-suggestive (according to the World Cancer Research Fund/American Institute for Cancer Research [WCRF/AICR]) preventive factors are foods containing lycopene, selenium and foods containing selenium,  $\alpha$ -tocopherol and foods containing  $\alpha$ -tocopherol, and legumes; in contrast, diets high in calcium, milk/dairy products, and processed meat are potentially modifiable risk factors. Relevant antioxidant vitamins and minerals are not specific to PCa but may be applicable for prevention of cancers in general. Legumes are of interest because they contain polyphenols, including isoflavones and daizein (and its metabolite, equol, in particular, which is a biologically active phytoestrogen.)<sup>11</sup> Milk/dairy products appear critical, not because they are major sources of calcium, but because they contain various growth or promotion factors, including insulin-like growth factor 1 and estrogen. Processed meat appears to be a food representative of an Americanized/Westernized diet and is one of the main sources of not only animal proteins but also iron (a redox radical) and cholesterol (a precursor of steroids, testosterone, and estrogen).<sup>12</sup>

Smoking should not be overlooked, as it is a single potent multi-targeting carcinogen.<sup>13</sup> Alcohol acts as a carcinogen via alcohol dehydrogenase 1B and acetaldehyde dehydrogenase 2 genetic polymorphisms (GPs).<sup>14</sup> Physical activity/exercise and participation in sports reduce insulin levels and insulin sensitivity, as well as the risk of diabetes mellitus. Both alcohol consumption and physical activity/sports modify syntheses of steroids, testosterone, and estrogen from cholesterol and change testosterone and estrogen levels and

Address for correspondence. Dr. Shinkan Tokudome, Department of Nutritional Epidemiology, National Institute of Health and Nutrition, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162-8636, Japan (e-mail: tokudome2013@gmail.com).

the testosterone:estrogen ratio by way of 5 $\alpha$ -reductase GPs.<sup>15</sup> Intake of vitamin D and sunlight exposure with vitamin D receptor GPs, including Fok-I, may modulate PCa carcinogenesis via cell cycle regulation and apoptosis.

For secondary prevention, controversial findings have been reported among several randomized controlled trials (RCTs) investigating possible PCa mortality-reducing effects of prostate-specific antigen (PSA)-based screening in the European countries<sup>16</sup> and in the United States.<sup>17</sup> The conflicting, inconclusive nature of these findings may be due to biases, including selection and information biases, based at least in part on the higher prevalences of PCa and PSA testing in these countries compared to Asian countries. An RCT or case-control study should be conducted to assess the effectiveness and test performance (including sensitivity, specificity, and positive predictive value) of PSA-based screening in Asian countries, which have a similar genetic background and lifestyle factors as well as lower prevalences of PCa and PSA test compared to Western countries.

## ACKNOWLEDGMENT

Conflicts of interest: None declared.

## REFERENCES

1. Fu YQ, Zheng JS, Yang B, Li D. Effect of individual omega-3 fatty acids on the risk of prostate cancer: a systematic review and dose-response meta-analysis of prospective cohort studies. *J Epidemiol*. 2015;25:261–74.
2. Lands WE. Long-term fat intake and biomarkers. *Am J Clin Nutr*. 1995;61 Suppl:721S–5S.
3. Okuyama H. High n-6 to n-3 ratio of dietary fatty acids rather than serum cholesterol as a major risk factor for coronary heart disease. *Eur J Lipid Sci Technol*. 2001;103:418–22.
4. Wakabayashi K. NSAIDs as cancer preventive agents. *Asian Pac J Cancer Prev*. 2000;1:97–113.
5. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. *J Natl Cancer Inst*. 2002;94:252–66.
6. Simopoulos AP. The importance of the omega-6/omega-3 fatty acid ratio in cardiovascular disease and other chronic diseases. *Exp Biol Med (Maywood)*. 2008;233:674–88.
7. Pauwels EK, Kairemo K. Fatty acid facts, part II: role in the prevention of carcinogenesis, or, more fish on the dish? *Drug News Perspect*. 2008;21:504–10.
8. Tokudome S, Kuriki K, Yokoyama Y, Sasaki M, Joh T, Kamiya T, et al. Dietary n-3/long-chain n-3 polyunsaturated fatty acids for prevention of sporadic colorectal tumors: a randomized controlled trial in polypectomized participants. *Prostaglandins Leukot Essent Fatty Acids*. 2015 Mar;94:1–11.
9. Tokudome S, Ando R, Ichikawa Y, Ichikawa H, Imaeda N, Goto C, et al. Re: Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial. *J Natl Cancer Inst*. 2014 Apr;106(4):dju020.
10. World Cancer Research Fund/American Institute for Cancer Research. Food, Nutrition, Physical Activity, and the Prevention of Cancer: a Global Perspective. Washington, DC: American Institute for Cancer Research; 2007.
11. Akaza H, Miyanaga N, Takashima N, Naito S, Hirao Y, Tsukamoto T, et al. Comparisons of percent equol producers between prostate cancer patients and controls: case-controlled studies of isoflavones in Japanese, Korean and American residents. *Jpn J Clin Oncol*. 2004;34:86–9.
12. Tokudome Y, Imaeda N, Ikeda M, Kitagawa I, Fujiwara N, Tokudome S. Foods contributing to absolute intake and variance in intake of fat, fatty acids and cholesterol in middle-aged Japanese. *J Epidemiol*. 1999;9:78–90.
13. Carter BD, Abnet CC, Feskanich D, Freedman ND, Hartge P, Lewis CE, et al. Smoking and mortality—beyond established causes. *N Engl J Med*. 2015;372:631–40.
14. Takeshita T, Morimoto K, Mao X, Hashimoto T, Furuyama J. Characterization of the three genotypes of low Km aldehyde dehydrogenase in a Japanese population. *Hum Genet*. 1994;94:217–23.
15. Cuzick J, Thorat MA, Andriole G, Brawley OW, Brown PH, Culig Z, et al. Prevention and early detection of prostate cancer. *Lancet Oncol*. 2014;15:e484–92.
16. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Screening and prostate cancer mortality in a randomized European study. *N Engl J Med*. 2009;360:1320–8.
17. Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, et al; PLCO Project Team. Mortality results from a randomized prostate-cancer screening trial. *N Engl J Med*. 2009;360:1310–9.